"Clinical data to date show that ZEN-3694 is active, safe, and well differentiated and will be presented at an upcoming scientific meeting."

My guess is Zenith will present at the 30th EORTC-NCI-AACR SYMPOSIUM: Molecular Targets and Cancer Therapeutics meeting Nov 13-16, 2018 in Dublin. The abstract dealine is coming up June 20 but late breaking submissions accepted Sep 21-28. There is a 2.5 hour session on Fri Nov 16th (see below) that seems well suited to bromodomain inhibition and prostate cancer. The first hour is already scheduled with a few speakers, but the remaining time is for Oral and Late Breaking Abstracts. Note that de Bono was principal investigator on the recent Phase 4 enzalutamide paper and also a recent prostate cancer/BET inhibitor publication.

Plenary Session 10: New Drugs in Clinical Trials: The Therapeutics of the Future

Chairs: E. Raymond (France), K. Flaherty (USA)

14:00 New epigenetic targets; Speaker: J.S. de Bono (United Kingdom)

14:20 The development of degraders; Speaker: R. Deshaies (USA)

14:40 New twists with topoisomerase inhibitors; Speaker: Y. Pommier (USA)

"Hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR), the 2018 Symposium brings together academics, scientists and pharmaceutical industry representatives from across the globe to discuss the latest innovations in drug development, target selection and the impact of new discoveries in molecular biology.

Building on the success and focus of previous highly acclaimed symposiums, this drug development and translational research meeting, focusing on preclinical and phase I studies, will enable delegates to have in-depth scientific discussions on the latest developments in targets and drugs."